Chlordiazepoxide/clidinium

Limits on what this shows

• Null findings: Clonazepam inactive; ADP:O unchanged, meaning coupling stayed intact [14]; complex IV unaffected [13].

Ingredient

Chlordiazepoxide side only (benzodiazepine class). Nothing retrieved concerns clidinium and mitochondria. Direction: functional inhibition in vitro, not a nutrient depletion.

Regulatory status

No mitochondrial statement in any retrieved label [1][2][3][4][5].

Population evidence

None in humans. Colleoni 1996 [13] (abstract via OpenAlex): midazolam at 0.1 to 0.75 mM depressed ADP-induced oxygen consumption and oxidative phosphorylation of rat liver mitochondria with substrates entering at several steps, but not with ascorbate plus TMPD (complex IV); it lowered complex I and III activity, also inhibited complex II, and did not change citrate synthase. The authors state the effects are probably not related to its action as a benzodiazepine and are likely mediated by mitochondrial receptors. Hirsch 1989 [14] (partial text via PubMed and a publisher PDF, read through summarizing fetch tools; abstract not available from OpenAlex): ten compounds including Ro5-4864, PK11195, diazepam and flunitrazepam raised state IV and lowered state III respiration, lowering the respiratory control ratio, with ADP:O ratios unchanged and a correlation of r = 0.95 between binding affinity and potency; clonazepam showed no mitochondrial effect and negligible binding.

Chlordiazepoxide-specific

Davis, Gatz and Jones 1971 [12] tested chlordiazepoxide and diazepam on respiration and oxidative phosphorylation in rat brain mitochondria. Only the title, authors, journal and year were retrieved. The abstract was absent from the records and the publisher page was blocked, so direction and concentration are unknown and the paper is not used for the grade.

Class cohort test

Chlordiazepoxide was NOT in either opened cohort (midazolam [13]; Ro5-4864, PK11195, diazepam, flunitrazepam, clonazepam and others [14]). Tier C for this drug, capped at yellow. The class is not uniform: clonazepam was inactive, so a class effect cannot be assumed for chlordiazepoxide. Sibling dossiers for other benzodiazepines were not available to open (see Overlap map) and nothing is borrowed from them.

Mechanism

Proposed by the sources as binding to mitochondrial benzodiazepine receptors, with electron transport inhibition at complexes I, II and III in the midazolam work. Not shown for chlordiazepoxide.

Counter-evidence held on record

Counter-evidence and limits The midazolam concentrations were in the millimolar range, and no retrieved source compares them with plasma or tissue exposure from chlordiazepoxide. All data are isolated rat mitochondria. No human, in vivo or clinical mitochondrial measure was found. Framing caution Not a claim that chlordiazepoxide or Librax damages mitochondria in people, and not a reason to supplement CoQ10 or any other nutrient.

Limits on what this shows

• Null findings: No result in any opened study showed an unchanged redox marker for a benzodiazepine, but the signals are not consistent: protective in diazepam stress models [21][22] and in vitro [24], higher oxidative markers after alprazolam [25] and in clonazepam withdrawal [23]. This inconsistency is the main reason the entry is kept at yellow with no direction claimed for chlordiazepoxide.
• At-risk subgroups: Not defined. The only human data are perioperative transplant patients.

Ingredient

Chlordiazepoxide side only (benzodiazepine class). No redox study of clidinium was located. Direction: mixed. This is a disturbance of redox markers in specific experimental settings, not a nutrient depletion, and no antioxidant nutrient was measured.

Regulatory status

No oxidative stress or antioxidant statement in any retrieved label [1][2][3][4][5].

Population evidence

Human: Can 2017 [25], randomized trial, 82 renal transplant donors and recipients in four groups; alprazolam 0.5 mg orally one hour before surgery versus no premedication; serum advanced oxidative protein products, total thiol, free hemoglobin, ischemia-modified albumin and sialic acid were measured at several time points. Alprazolam groups had higher oxidative parameters than controls, and the authors conclude alprazolam does not improve redox homeostasis (abstract only, read as a reconstructed OpenAlex abstract; effect sizes and CIs not retrieved). Animal and in vitro: Mendez-Cuesta 2011 [21], rats, diazepam 1 mg/kg i.p. before 24 h restraint; stress raised striatal lipid peroxidation 73% and lowered superoxide dismutase 54% and mitochondrial function 35%, and diazepam pretreatment lowered lipid peroxidation 68% below the stress group and raised mitochondrial function 18% above it (abstract only, group sizes not retrieved). Benha University group [22], 120 male rats in 6 groups, diazepam 0.9 mg/kg after sleep-deprivation anxiety; diazepam raised SOD, catalase and glutathione and lowered MDA and ACTH relative to the untreated anxiety group (journal page abstract via a summarizing fetch tool). Baslam 2024 [23], rats, clonazepam escalating from 1.5 to 6 mg/kg/day i.p. for 30 days, n = 6 per group; in the withdrawal group hippocampal MDA rose and catalase and SOD fell (the fetch tool relayed MDA 35.21 versus 11.01 in vehicle controls, units not retrieved). Oliveira 2016 [24], mouse brain homogenate with in vitro induced oxidative stress; clonazepam at 50, 100 or 200 ug/ml lowered TBARS and nitrite, restored catalase and, at the lowest concentration, raised glutathione.

Class cohort test

Chlordiazepoxide was NOT in the cohort of any of [21][22][23][24][25]. Drugs studied: diazepam [21][22], clonazepam [23][24], alprazolam [25]. Tier C for this drug, capped at yellow. Chlordiazepoxide was not found in any redox study located in two search rounds. Sibling dossiers for other benzodiazepines were not available to open, and nothing is borrowed from them.

Mechanism

Not established for any of these drugs. The rodent studies attribute the protective pattern to attenuation of stress-induced lipid peroxidation, not to direct radical scavenging by the drug, and the clonazepam withdrawal signal appears in a dependence and withdrawal state. For chlordiazepoxide specifically no mechanism is shown.

Counter-evidence held on record

Counter-evidence and confounding The human trial [25] is a single dose in the setting of major surgery and chronic kidney disease, where surgical stress dominates redox markers, and it does not test chlordiazepoxide. The rodent stress models measure a drug against a stressor, not against untreated baseline, and the clonazepam withdrawal result reflects dependence and withdrawal, not ordinary exposure. In vitro concentrations (50 to 200 ug/ml) are far above any retrieved plasma level. The mitochondrial complex I and III inhibition seen with midazolam [13] was not accompanied by a reactive oxygen species measurement and is not counted here. Framing caution Not a claim that Librax raises or lowers oxidative stress in people, not an antioxidant-depletion claim, and not a reason to supplement any antioxidant. No supplement dose appears in this dossier.

Limits on what this shows

• Why no grade: Dual condition met on what was retrievable: no Tier B or C copper source opened for chlordiazepoxide or any benzodiazepine, and no circulating consumer claim about copper for this drug seen. Kept independent of Iron (Hard Rule 7). Not a finding of safety. Re-check required when PubMed and Crossref access returns.

What was searched

Round 1 (2026-10-06): web search "chlordiazepoxide vitamin deficiency OR folate OR zinc OR iron OR copper benzodiazepine nutrient depletion" (surfaced the Surrey thesis [11], a Tier D page [19] and consumer pages; nothing on copper); Crossref query on chlordiazepoxide, vitamin deficiency, folate and nutrient (generic B12 and folate items only); label review, no mineral mentioned in [1][2][3][4][5]. Round 2 (2026-10-07): web search "benzodiazepine serum iron ferritin OR serum copper ceruloplasmin patients" (laboratory test catalog pages for ceruloplasmin and serum copper and unrelated papers; no benzodiazepine study); "chlordiazepoxide serum iron OR ferritin OR copper OR zinc levels patients treated" (chlordiazepoxide drug-level assay catalog pages, an antiepileptic zinc and copper study, a thalassemia item); "benzodiazepines serum copper zinc trace elements anxiety patients diazepam treatment levels" (zinc-and-anxiety review and consumer pages, which run from nutrient status to anxiety, not drug to nutrient; one PMC hit returned a bot-verification page and was not read). The one relevant-looking item opened, Kuzuya 1993 [26], studied carbamazepine, phenobarbital, phenytoin and valproate only (serum copper rose about 25 to 39% in 114 patients versus 30 controls) and no benzodiazepine, so it is excluded by the cohort test and not used.

Channel outcomes

Partly tooling-limited. Web search ran for copper in round 2 and returned nothing on benzodiazepines. Crossref (two phrasings), OpenAlex search, Europe PMC search and the PubMed listing page returned 429 or 400 errors, so no database search for benzodiazepine copper studies completed. Genuine gap in what could be opened, not proof of absence.

Limits on what this shows

• Why no grade: Dual condition met on what was retrievable: no Tier B or C iron source opened for chlordiazepoxide or any benzodiazepine, and no circulating iron claim for this drug seen. Kept independent of Copper (Hard Rule 7). Not reassurance. Any anemia signal would be an outcome and belongs under Oxygen delivery only if iron or another nutrient were measured (Hard Rule 2). Re-check required when PubMed and Crossref access returns.

What was searched

Round 1: the same combined nutrient web search and Crossref queries as Copper, plus label review; no acid-suppressing, chelating or binding mechanism is described in the retrieved label text. Round 2 (2026-10-07): web search "benzodiazepine serum iron ferritin OR serum copper ceruloplasmin patients", "chlordiazepoxide serum iron OR ferritin OR copper OR zinc levels patients treated" and "benzodiazepine iron deficiency OR iron absorption OR ferritin association study" (the last returned a psychiatry iron-deficiency review title, several PMC and publisher records and rodent iron-absorption items; the two records opened, a 1972 rat study of intestinal ferritin in inflammation and a 1970 chloroform hemolysis study, did not involve any benzodiazepine; the remaining hits were titles only and not opened). Crossref "benzodiazepine serum iron ferritin" returned 429, and OpenAlex and Europe PMC searches returned 429.

Channel outcomes

Partly tooling-limited, same as Copper. Web search completed for iron and returned no benzodiazepine iron study; every database search channel was rate-limited, so coverage of PubMed-indexed human studies is incomplete.

Limits on what this shows

• Null findings: Alprazolam, 5 days, no diversity or abundance effect [16].

Ingredient

Chlordiazepoxide side only, via the benzodiazepine class. No microbiome study of clidinium or other antimuscarinics was located. Direction: composition shift (a disturbance, not a depletion).

Regulatory status

No microbiome statement in the retrieved labels [1][2][3][4][5].

Population evidence

Vich Vila 2020 [15] (read via a summarizing fetch tool): metagenomic analysis of three Dutch cohorts (LifeLines-DEEP 1,124; IBD 454; IBS 305; 1,883 samples) covering 41 medication categories. Benzodiazepines were analyzed as a class; in the IBD cohort their use was associated with higher Haemophilus parainfluenzae (FDR 0.008). No result for the IBS cohort was seen in the retrieved text, and individual benzodiazepines were not named. Manook 2023 [16] (via a summarizing fetch tool): balanced crossover in 36 healthy men comparing etifoxine, alprazolam and others for 5 days; no relevant treatment effect on alpha or beta diversity, and differential abundance changed only for etifoxine.

Class cohort test

Chlordiazepoxide NOT named in either study (alprazolam was the only named benzodiazepine, in [16]). Tier C, yellow. The IBS cohort in [15] matches the Librax indication but benzodiazepine use there was not individually characterized in what was retrieved.

Mechanism

Not established. Clidinium slows gut motility and could in principle change transit-dependent microbial communities, but no retrieved source tests this, so it stays hypothetical. A 2018 in vitro screen of 1,197 drugs against gut bacteria [17] was opened, but benzodiazepines and anticholinergics were not discussed in the accessible text and its supplementary hit table could not be read.

Counter-evidence held on record

Counter-evidence and confounding Observational medication associations in IBD and IBS cohorts are confounded by disease, co-medications and diet. The only interventional data (alprazolam, 5 days) were null and short. Framing caution Not a claim of dysbiosis from Librax. Do not extend proton pump inhibitor or antibiotic microbiome findings to this product.

Limits on what this shows

• Null findings: ADP:O unchanged [14]; clonazepam inactive [14]; no ATP content, cellular energy charge or in vivo energy measurement was located.

Ingredient

Chlordiazepoxide side only (benzodiazepine class). Direction: reduced oxidative phosphorylation rate in vitro, not a depletion.

Regulatory status

None in the retrieved labels [1][2][3][4][5].

Population evidence

None in humans. Colleoni 1996 [13]: midazolam depressed ADP-induced oxygen consumption and oxidative phosphorylation in rat liver mitochondria at 0.1 to 0.75 mM. Hirsch 1989 [14]: state III respiration (the ADP-driven, ATP-producing state) fell and state IV rose for receptor ligands including diazepam, with ADP:O unchanged, i.e. no loss of coupling efficiency; clonazepam inactive. These are the same two sources as the Mitochondrial burden entry and are not independent confirmation.

Class cohort test

Chlordiazepoxide NOT in the cohorts [13][14]. The 1971 chlordiazepoxide paper [12] was seen by title only. Tier C, yellow, and weaker than the mitochondrial entry because oxygen consumption and ADP:O are surrogates for ATP synthesis, not ATP measurements.

Mechanism

Present in vitro for some benzodiazepines (see Mitochondrial burden). Not shown for chlordiazepoxide or clidinium.

Counter-evidence held on record

Counter-evidence and limits Same concentration caveat as the mitochondrial entry. Fatigue or sedation from the drug is a pharmacologic effect and is not evidence of low ATP (Hard Rule 2). Framing caution Not a "low energy" claim. Do not present this as reduced cellular energy production in patients.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source on oxygen-carrying capacity was opened for chlordiazepoxide or any benzodiazepine, and no circulating oxygen-delivery claim was seen. The red-cell binding-site study [28] shows only that a binding site exists and is not an oxygen delivery effect. Labeled neutropenia, thrombocytopenia and hepatic events are drug adverse outcomes, not oxygen delivery and not nutrient deficiencies (Hard Rule 2), and benzodiazepine respiratory depression is a pharmacologic effect that would also not be filed here. Kept independent of ATP production (Hard Rule 7). Not a finding of safety.

What was searched

Round 1: web search "chlordiazepoxide methemoglobinemia OR hemolytic anemia OR aplastic anemia OR agranulocytosis case report" (generic agranulocytosis case reports; none opened); Crossref "chlordiazepoxide blood dyscrasia pancytopenia hemolysis" (no relevant items); labels: blood dyscrasias including agranulocytosis, jaundice and hepatic dysfunction occasionally reported, with periodic blood counts advised in prolonged therapy [1]; agranulocytosis, granulocytopenia and leukopenia in the Canadian monograph [5]. A 2001 case report of acute thrombocytopenic purpura with chlordiazepoxide and clidinium [18] was seen as metadata only. Round 2 (2026-10-07): web search "chlordiazepoxide erythrocytes hemolysis OR methemoglobin OR red blood cell in vitro" (hemolysis assay product sheets and non-benzodiazepine methemoglobin items; none opened as relevant); "chlordiazepoxide anemia hemoglobin hematocrit patients long-term benzodiazepine users" (opened: a record of Lechin 1994 on peripheral blood immunological parameters in long-term benzodiazepine users [27], which reports immune parameters, names no benzodiazepine in its abstract and no hemoglobin or red-cell result; a PMC hit was blocked); "benzodiazepine use association anemia OR hemoglobin cohort study older adults" (opened a 2001 benzodiazepine use survey in the elderly and a 2020 Brazilian benzodiazepine utilization study; neither measured anemia or hemoglobin); "diazepam OR benzodiazepine hemolytic anemia OR methemoglobinemia case report" (dapsone and other non-benzodiazepine methemoglobinemia reports; none involving a benzodiazepine seen); "chlordiazepoxide arterial oxygen tension PaO2 hypoxemia COPD OR sleep study" (opened a 1976 sleep blood-gas study in chronic ventilatory failure that studied no benzodiazepine; JCI and PMC records not read); "benzodiazepine receptor ligand erythrocyte membrane" (opened Olson 1988 [28], peripheral-type benzodiazepine binding sites on human red cell membranes; ligands PK 11195, Ro 5-4864, flunitrazepam, clonazepam, no chlordiazepoxide, and a binding result only, with no hemoglobin, oxygen affinity or red-cell function measured).

Channel outcomes

Mixed. Open web search completed several phrasings for hemoglobin, hemolysis, methemoglobin and arterial oxygen and gave no benzodiazepine red-cell result. PubMed listing, Crossref, OpenAlex and Europe PMC searches were rate-limited, and PMC article pages returned bot-verification pages, so database coverage is partial.